Patents Assigned to Oncomatryx Biopharma, S.L.
-
Patent number: 10864278Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: October 16, 2018Date of Patent: December 15, 2020Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20190105406Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p ??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: October 16, 2018Publication date: April 11, 2019Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 10137202Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: February 4, 2015Date of Patent: November 27, 2018Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 10004812Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: GrantFiled: February 4, 2015Date of Patent: June 26, 2018Assignee: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Patent number: 9702879Abstract: The present invention relates to in vitro methods and products for detecting the presence of an invasive carcinoma in an individual, for determining and/or predicting the stage and/or invasiveness of said carcinoma in an individual, or for monitoring the effect of the therapy administered to an individual who has said carcinoma based on col11a1 gene and proCOL11A1 protein expression. The invention also relates to the search for, identification, development and evaluation of the efficacy of compounds for therapy for said carcinoma, for the purpose of developing new medicinal products. The invention also relates to agents inhibiting proCOL11A1 protein expression and/or activity, and/or the effects of this expression.Type: GrantFiled: August 8, 2012Date of Patent: July 11, 2017Assignee: Oncomatryx Biopharma, S.L.Inventors: Luis Barneo Serra, Carmen Garcia Pravia, Juan Ramon De Los Toyos Gonzalez, Marcos Garcia Ocana, Jose Fernando Vazquez Villa, Nelson Fuentes Martinez, Jokin Del Amo Iribarren, Laureano Simon Buela
-
Publication number: 20170007716Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: February 4, 2015Publication date: January 12, 2017Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon
-
Publication number: 20170007714Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.Type: ApplicationFiled: February 4, 2015Publication date: January 12, 2017Applicant: Oncomatryx Biopharma, S.L.Inventors: Roland Kontermann, Klaus Pfizenmaier, Cristina Ferrer, Myriam Fabre, Laureano Simon